Zepbound is approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and increased physical activity. Whether it belongs in your care depends on your diagnosis, existing treatment, health history and a clinician’s assessment. Zepbound prescribing information, section 1.
This guide concerns the FDA-approved brand Zepbound. Its OSA indication should not be assumed to apply to compounded tirzepatide, Mounjaro or another medicine. This educational guide does not confirm that brand-name Zepbound is available through Majesta. Discuss OSA treatment with your sleep clinician.
If you already use positive airway pressure (PAP), such as CPAP, starting Zepbound does not automatically replace it. The practical next step is to prepare a conversation with your sleep clinician and prescriber. The printable discussion card below helps organize that discussion without diagnosing you or deciding eligibility.
Start with your sleep diagnosis
The indication described here has three parts: obstructive sleep apnea, moderate-to-severe disease, and adults with obesity. It does not establish the same sleep-apnea use for central apnea, mild OSA, children or adults without obesity. Your clinicians must interpret your situation; the wording is not a personal eligibility test. Zepbound prescribing information, section 1.
The National Heart, Lung, and Blood Institute (NHLBI) explains that sleep studies can help identify which type of sleep apnea you have and how serious it is. A sleep diary, with notes about how long and how well you sleep and how sleepy you feel during the day, can also help your provider. Notes like these do not, by themselves, establish the type or severity of sleep apnea. NHLBI: diagnosing sleep apnea.
Bring an existing sleep-study report, recent sleep or symptom notes, and a list of current medicines, including other diabetes or weight-management medicines. Note your current PAP treatment and any problems to discuss. Ask the office which records are useful; this guide does not require a new test or a particular PAP download. Rather than translating a single number into a treatment decision, ask:
- What type and severity does this report establish?
- Which terms and measurements matter for my care?
- Does my situation match the population described in the Zepbound label?
- Is any further evaluation needed before we discuss medication?
If you have not had an evaluation, ask about that first. You do not need to arrive with a diagnosis or calculate an eligibility score yourself.
Keep three decisions separate
Diagnosis: Your clinician evaluates the sleep disorder and the evidence supporting it.
Treatment: Your clinicians consider whether Zepbound is appropriate alongside your current sleep-apnea care, health history and other medicines. Ask which clinician will assess the medicine and which will manage PAP follow-up. If they are different people, clarify how they will share the plan.
Coverage: Your plan determines what benefits and authorization requirements apply to a particular prescription. An insurance rule is not a diagnosis or treatment instruction.
The FDA announced Zepbound’s OSA approval on December 20, 2024. That announcement explains the approval’s background; the current prescribing information is the appropriate source for current product warnings. FDA approval announcement, Zepbound prescribing information.
For plan-specific questions, use our Cigna, Aetna or UnitedHealthcare coverage guide. Confirm the documents that apply to your own plan; these guides do not promise coverage.
What if you already use PAP?
Tell both clinicians what treatment you currently use, who manages it and what problems you have experienced. PAP is the most common treatment for sleep apnea, according to NHLBI. Different PAP machines exist, and the appropriate type is a question for your provider. NHLBI: sleep apnea treatment.
The Zepbound OSA studies included people already using PAP and people unable or unwilling to use it. They did not evaluate whether or when people who were already using PAP consistently should stop it. A pause used for study measurements is not a home-care instruction. Zepbound prescribing information, section 14.2.
Do not stop PAP simply because you start Zepbound or feel better. Ask your sleep clinician how and when your existing treatment should be reassessed. Report PAP problems or side effects, and follow the instructions appropriate to your situation.
Useful questions include: Who manages my PAP treatment? Which changes should I report? How will we decide whether reassessment is needed? Avoid setting your own timetable for pressure changes or stopping treatment.
Agree on what follow-up will assess
Ask what information your clinicians want to review: symptoms, sleep-study findings, current treatment experience or other measures relevant to your situation. Also ask when the next review should occur and which office to contact between visits.
A change you notice and a measured study outcome are different kinds of information. Keep notes about both, without assuming that feeling less sleepy proves your sleep apnea has resolved.
The trials describe outcomes in particular study populations, not a prediction for you. Our Zepbound clinical-study results guide explains the reported outcomes and their limits. Bring questions about those results to your clinician rather than using a study average as your personal target.
Printable sleep-visit discussion card
Copy this card to a private note or print it. Use information you already have; ask your clinician which records are useful. It is not an online form, prescription request or eligibility test. Avoid identifying or medical information in publicly shared copies.
- Sleep report: What is the report date? What type and severity does it establish?
Notes: _____
- Current care: What treatment am I using, who manages it, and which problems should we discuss?
Notes: _____
- Label fit: Do my diagnosis and health history fit the labeled population?
Notes: _____
- Expectations: Which benefits, uncertainties and risks matter for me?
Notes: _____
- Follow-up: What will we review, when, and who decides about reassessment?
Notes: _____
- Safety: Which medicines, conditions, pregnancy plans or procedures should we discuss?
Notes: _____
- Contact: Which symptoms need prompt contact? Who handles medicine concerns and PAP concerns?
Notes: _____
Leave an unfamiliar field blank and ask about it. The card is meant to make the visit more useful, not to determine a treatment outcome before you arrive. After the visit, write one agreed next step, its date and the clinician responsible.
Bring safety questions to the prescriber
The label carries a boxed warning about thyroid C-cell tumors seen in rodents; the relevance to humans is unknown. Zepbound must not be used by people with a personal or family history of medullary thyroid carcinoma, by people with multiple endocrine neoplasia syndrome type 2 (MEN 2), or by people who have had a serious allergic reaction to tirzepatide or its ingredients. Zepbound prescribing information, boxed warning and section 4.
Tell the prescriber about other medicines and relevant conditions, including stomach-emptying problems, pancreatic or gallbladder history, dehydration or kidney problems, and diabetes medicines. Ask about low blood sugar, especially if you use insulin or medicines that increase insulin release. If you have type 2 diabetes and a history of diabetic retinopathy, ask about monitoring during treatment. Discuss pregnancy, pregnancy plans and upcoming anesthesia or deep sedation. These topics are not all contraindications, but they can affect assessment and care. If you use oral hormonal contraception, ask your prescriber how Zepbound may affect it and what precautions are needed when starting or increasing the dose. Zepbound prescribing information, sections 7.2 and 8.3.
The label directs discontinuation when pregnancy is recognized. It also warns about serious gastrointestinal problems and other risks. Ask which symptoms require prompt action and what to do if they occur. Do not create your own dosing or procedure-related holding schedule. Zepbound prescribing information, sections 5 and 8.1.
Using Zepbound with another tirzepatide product or a glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. Ask your prescriber to check your medicine list for these combinations. Review the complete prescribing information with your clinician; this section is not a full safety summary.
Sources accessed October 18, 2026. Educational information about the FDA-approved Zepbound product. Individual diagnosis and treatment require an assessment by a qualified clinician.
Frequently Asked Questions
Can symptoms alone show that I qualify?
No. Symptoms are useful information for a clinician, but a discussion card cannot establish the diagnosis, severity or suitability of medication. Ask whether you need a sleep evaluation.
Does starting Zepbound mean I can stop PAP?
No automatic conclusion follows. The studies did not evaluate whether or when people who were already using PAP consistently should stop it. Discuss your existing treatment and any problems with the clinician managing it.
What should I bring to the appointment?
An existing sleep-study report, a record of sleep symptoms, current treatment information and your medicine list can organize the conversation. Ask the office which records it needs; this guide does not require a new test or PAP download.
Will a clinician’s recommendation guarantee coverage?
No. Clinical suitability and insurance benefits are separate decisions. Confirm the applicable benefit documents, authorization process and costs with your plan.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Zepbound (tirzepatide) U.S. prescribing information, document ZEP-0016-USPI-20260828 · Eli Lilly and Company · accessed
- 2.Zepbound obstructive sleep apnea approval announcement, December 20, 2024 · U.S. Food and Drug Administration · accessed
- 3.Sleep apnea diagnosis · National Heart, Lung, and Blood Institute, National Institutes of Health · accessed
- 4.Sleep apnea treatment · National Heart, Lung, and Blood Institute, National Institutes of Health · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them